VistaGen Therapeutics, Inc.

VTGN • Biotechnology

$0.24

▼ -0.00 (-1.38%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$10.44M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.03Liquidez saludable · 3.67Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:17 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.24

Change-1.38%

Shares Out42.98M

Market Cap$10.44M

Enterprise Value$-20.51M

52W Range0.20 - 5.14

Beta0.38

P/E-0.15

P/S4.17

P/B0.43

P/FCF-0.17

EV/Sales-8.20

Price$0.24

Change-1.38%

Shares Out42.98M

Market Cap$10.44M

Enterprise Value$-20.51M

52W Range0.20 - 5.14

Beta0.38

P/E-0.15

P/S4.17

P/B0.43

P/FCF-0.17

EV/Sales-8.20

EV/EBITDA0.30

EV/FCF0.33

Earnings Yield-647.98%

FCF Yield-598.16%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-56.84%

Profit Margin-54.91%

Debt/Eq0.03

Current Ratio3.67

Quick Ratio3.67

Target$0.95

Target Upside291.27%

Target Median$0.95

Target Range0.90 - 1.00

Volume891.43K

Avg Volume3.13M

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

27/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

70/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.03Liquidez saludable · 3.67Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

VTGN

Analyst sentiment

Based on 7 analyst votes · 2026-09-05

71/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-16

Bajo

$0.90

Promedio

$0.95

Mediana

$0.95

Alto

$1.00

Resumen de la compañía

IPO: 6/21/2011

Industria: Biotechnology

P/B i: 0.43

Deuda / Patrimonio i: 0.03

Margen operativo: -5683.69%

Margen neto: -5491.33%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.03

Ratio corriente: 3.67

Ratio rápido: 3.67

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Williamson Douglas J

Transacción: 07/29/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/31/2026

Tipo

OTRO

Williamson Douglas J

Transacción: 07/29/2026

COMPRA

Cambio

+40,826

Precio

$0.24

Presentación

07/31/2026

Tipo

COMPRA

Singh Shawn

Transacción: 06/30/2026

COMPRA

Cambio

+36,818

Precio

$0.19

Presentación

07/02/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Williamson Douglas J	OTRO	0	Not reported	07/29/2026	07/31/2026
Williamson Douglas J	COMPRA	+40,826	$0.24	07/29/2026	07/31/2026
Singh Shawn	COMPRA	+36,818	$0.19	06/30/2026	07/02/2026
Tressler Nick B.	COMPRA	+11,712	$0.19	06/30/2026	07/02/2026
Adler Reid G.	COMPRA	+36,818	$0.19	06/30/2026	07/02/2026
Angelov Angel S	OTRO	0	Not reported	05/18/2026	05/19/2026
Angelov Angel S	COMPRA	+150,000	$0.60	05/18/2026	05/19/2026
Adler Reid G.	COMPRA	+18,753	$0.54	04/07/2026	04/09/2026
Adler Reid G.	COMPRA	+56,247	$0.54	04/07/2026	04/09/2026
Cote Elissa S.	COMPRA	+75,000	$0.54	04/07/2026	04/09/2026
Prince Joshua S.	COMPRA	+18,752	$0.54	04/07/2026	04/09/2026
Prince Joshua S.	COMPRA	+56,248	$0.54	04/07/2026	04/09/2026
Singh Shawn	COMPRA	+3,732	$0.54	04/07/2026	04/09/2026
Singh Shawn	COMPRA	+71,268	$0.54	04/07/2026	04/09/2026
Tressler Nick B.	COMPRA	+75,000	$0.54	04/07/2026	04/09/2026
Prince Joshua S.	COMPRA	+4,386	$0.56	12/31/2025	01/05/2026
Tressler Nick B.	OTRO	0	Not reported	12/01/2025	12/04/2025
Tressler Nick B.	COMPRA	+150,000	$4.43	12/01/2025	12/04/2025
Edick Paul R	OTRO	0	Not reported	10/27/2025	11/04/2025
Edick Paul R	COMPRA	+35,200	$3.90	10/27/2025	11/04/2025

Sobre la compañía

VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Fuente - Link

Competidores

ABOS ACTU AGEN CGTX HURA INO IRD MCRB SEER SPRO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

GlobeNewsWire

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder.

GlobeNewsWire

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.

GlobeNewsWire

Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.

GlobeNewsWire

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-06-15	-0.33667	-0.37	-0.03333
2026-02-12	-0.51	-0.45	0.06
2025-11-13	-0.51	-0.54	-0.03
2025-08-07	-0.47	-0.47	0
2025-06-17	-0.52	-0.43	0.09
2025-02-13	-0.48	-0.46	0.02
2024-11-07	-0.4	-0.42	-0.02
2024-08-13	-0.41	-0.35	0.06
2024-06-11	-0.34	-0.25	0.09
2024-02-13	-0.31	-0.22	0.09
2023-11-09	-0.68	-0.66	0.02
2023-08-10	-0.86	-0.94	-0.08